Markets

Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026

Jul 21, 2026 · 07:20 AM ET· updated 5h ago

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October

Why It Matters

Pasithea is showing early test results for a new cancer medicine at a big doctor conference. This is a step forward in testing, but it's still very early—we'll learn more from what doctors think about the results.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KTTA0.45

-0.02 (-4.27%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.